Clinical Trials Browser

INDUSTRY × Expanded_access × gilteritinib × Clear all

NCT03070093 2021-04-20

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Approved for marketing

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03409081 2018-09-13

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

No longer available

Other hematologic neoplasm

Leukemia, Myeloid, Acute